Skip to search formSkip to main contentSkip to account menu

vaccinia-CEA-TRICOM vaccine

Known as: rV-CEA(6D)-TRICOM, rV-CEA(6D)/TRICOM, vCEA-TRI 
A vaccine consisting of recombinant vaccinia virus encoding the tumor-associated antigen carcinoembryonic antigen (CEA) and a TRIad of COstimulatory… 
National Institutes of Health

Related topics

Related topics

6 relations
Carcinoembryonic AntigenCytotoxic T-LymphocytesGene Expression RegulationT-Cell Activation

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
The Requirement ofMultimodalTherapy ( Vaccine , LocalTumor Radiation , and Reduction of Suppressor Cells ) to Eliminate EstablishedTumors
Purpose:Numerous immune-based strategies are currently beingevaluated for cancer therapy in preclinicalmodels and clinical trials… 
Review
2004
Review
2004
Adjuvant Treatment of Colorectal Cancer: Towards Tumor-specific Immunotherapies
Colorectal cancer is one of the leading causes of cancer-related mortality. After a series of clinical trials, the adjuvant 5-FU… 
2004
2004
therapeutic vaccines for colorectal cancer
A number of cancer vaccine strategies for the treatment of colorectal cancer have entered clinical trials. Whole tumor cell… 
2001
2001
Technology evaluation: CEA-TRICOM, Therion Biologics Corp.
  • M. Morse
  • Current opinion in molecular therapeutics (Print)
  • 2001
  • Corpus ID: 37668406
Therion Biologics, the NCI and Aventis Pasteur are investigating CEA-TRICOM, a recombinant, pox virus-based vaccine that… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)